- Investing.com
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Metrics to compare | MYE0 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMYE0PeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −0.8x | −0.5x | |
PEG Ratio | 0.00 | 0.07 | 0.00 | |
Price/Book | 0.0x | 1.1x | 2.6x | |
Price / LTM Sales | 0.0x | 3.7x | 3.3x | |
Upside (Analyst Target) | 0.0% | 98.8% | 42.4% | |
Fair Value Upside | Unlock | 21.5% | 7.2% | Unlock |